Spectral Gini Index for Quantifying the Depth of Consciousness

Table 4

Population pharmacokinetic parameter estimates and interindividual variability of the pharmacokinetic models of propofol.

Index
SpE	0.796 (2.4, 9.2)	0.607 (2.9, 13.3)	1.47 (0.5, 52.6)	6.54 (3.0, 175.5)	0.089 (0.4, 33.5)
PE	0.698 (17.8, 14.4)	0.293 (43.0, 97.4)	1.18 (22.4, 44.4)	2.99 (46.5, 57.5)	0.1 (28.6, 70.1)
AE	0.852 (4.9, 14.7)	0.278 (1.5, 71.0)	1.12 (0.3, 52.1)	5.52 (8.0, 147.3)	0.117 (2.0, 33.0)
DFA	1.250 (2.4, 9.6)	1.530 (0.9, 3.1)	1.33 (12.0, 33.5)	7.73 (6.2, 150.0)	0.105 (10.3, 53.7)
SFS	4.17 (4.5, 16.6)	6.81 (4.2, 16.0)	1.1 (11.9, 42.7)	6.55 (18.6, 83.7)	0.146 (14.2, 53.9)
SpG	0.68 (11.3, 17.8)	0.826 (1.3, 3.44)	1.22 (0.3, 43.9)	5.73 (43.1, 198.8)	0.098 (14.4, 45.4)
BSpG	0.037 (28.7, 99.7)	0.367 (4.3, 46.9)	2.88 (10.2, 55.2)	3.85 (5.4, 126.5)	0.081 (5.1, 34.2)

Data are expressed estimate (RSE, % CV). A log-normal distribution of interindividual random variability was assumed. Residual random variability was modeled using additive error model. RSE: relative standard error = SE/mean × 100 (%). SE: standard error.